A changing treatment landscape for multiple sclerosis: challenges and opportunities

Multiple sclerosis (MS) is primarily an autoimmune disease of the central nervous system, but also encompasses prominent neurodegenerative aspects. A significant proportion of MS patients will develop neurological disability over time and up until recently treatment options have been limited. Howeve...

Full description

Saved in:
Bibliographic Details
Published in:Journal of internal medicine 2014-04, Vol.275 (4), p.364-381
Main Author: Piehl, F.
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - therapeutic use
Antibodies, Monoclonal - therapeutic use
biological therapies
Clinical Trials as Topic
Evidence-Based Medicine
Humans
Immunologic Factors - therapeutic use
immunomodulatory therapy
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - therapeutic use
Medicin och hälsovetenskap
Monitoring, Physiologic
multiple sclerosis
Multiple Sclerosis - drug therapy
randomized controlled trial
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple sclerosis (MS) is primarily an autoimmune disease of the central nervous system, but also encompasses prominent neurodegenerative aspects. A significant proportion of MS patients will develop neurological disability over time and up until recently treatment options have been limited. However, MS treatment is now at a stage of rapid progress, with several new drugs that have reached the market or will be launched in the near future. This provides new opportunities for individualized treatment, but also creates new challenges regarding monitoring of disease activity, long‐term safety issues and efficacy, not least in patients with progressive disease.
ISSN:0954-6820
1365-2796
1365-2796
DOI:10.1111/joim.12204